White House denies Trump is the ‘well-connected’ man who gained compassionate access to obesity drug in April

The White House has firmly rejected claims that President Trump had special access to a new obesity drug called retatrutide from Eli Lilly. The denial comes amidst speculation that Trump might have been the 'well-connected' individual mentioned who received compassionate access to the medication in April. This situation matters because it underscores the ongoing scrutiny of access to experimental drugs and the potential for preferential treatment by high-profile figures. The denial aims to quell concerns about the integrity of the drug approval process and ensure public trust in medical regulations.